Opus Genetics在关键性Lynx-3三期试验中为首位患者给药,评估0.75%酚妥拉明眼科溶液治疗角膜屈光手术患者中间视觉低对比度条件下视觉障碍的疗效

美股速递
Sep 04

Opus Genetics公司宣布,在其关键性Lynx-3三期临床试验中成功为第一位患者给药。该试验旨在评估0.75%酚妥拉明眼科溶液在治疗角膜屈光手术患者中间视觉、低对比度条件下视觉障碍方面的有效性和安全性。

这项重要的三期临床试验标志着该公司在眼科治疗领域取得的重要进展,为那些在中间光照和低对比度环境下出现视觉困扰的角膜屈光手术患者提供了新的治疗希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10